Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: A phase II study

Journal of Neurology

Volumn 260, Issue 2, 2013, Pages 489-497

  Morrow, Sarah A ^a   Smerbeck, Audrey ^b   Patrick, Kara ^b   Cookfair, Diane ^b   Weinstock Guttman, Bianca ^b   Benedict, Ralph H B ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

Cognition; Lisdexamfetamine; Multiple sclerosis; Treatment

Indexed keywords

LISDEXAMFETAMINE; PLACEBO;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; BRONCHITIS; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DECREASED APPETITE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; MULTIPLE SCLEROSIS; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; WORKING MEMORY; XEROSTOMIA;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DEXTROAMPHETAMINE; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY; MENTAL PROCESSES; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84878845699     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6663-7     Document Type: Article

References (54)

1. Hauser SL, Oksenberg JR, Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52:61-76
2. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549-558
3. Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685-691
4. Bobholz JA, Rao SM (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16:283-288
5. Beatty WW, Blanco CR, Wilbanks SL, Paul RH (1995) Demographic, clinical, and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehabil 9:167-173
6. Parmenter BA, Zivadinov R, Kerenyi L, Gavett R, Weinstock-Guttman B, Dwyer M, Garg N, Munschauer F, Benedict RH (2007) Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol 29:215-223
7. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B (2005) Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 231(1-2):29-34
8. Carone D, Benedict RH, Munschauer FE III, Fishman I, Weinstock-Guttman B (2005) Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J Int Neuropsychol Soc 11:574-583
9. Benedict RH, Priore RL, Miller C, Munschauer F, Jacobs L (2001) Personality disorder in multiple sclerosis correlates with cognitive impairment. J Neuropsychiatry Clin Neurosci 13:70-76
10. Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58:1602-1606
11. Benedict RH, Zivadinov R (2006) Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 245:67-72
12. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH et al (1995) A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating- remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1:118-135
13. The IFNB Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
14. Lee EH, Ma YL (1995) Amphetamine enhances memory retention and facilitates norepinephrine release from the hippocampus in rats. Brain Res Bull 37:411-416
15. Wright FK, White KG (2003) Effects of methylphenidate on working memory in pigeons. Cogn Affect Behav Neurosci 3:300-308
16. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12:268-275
17. Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH (2007) Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Exp Clin Psychopharmacol 15:123-133
18. Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:43-58
19. Pietrzak RH, Snyder PJ, Maruff P (2010) Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol 25:353-358
20. Magill RA, Waters WF, Bray GA, Volaufova J, Smith SR, Lieberman HR, McNevin N, Ryan DH (2003) Effects of tyrosine, phentermine, caffeine D-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation. Nutr Neurosci 6:237-246
21. Newhouse PA, Belenky G, Thomas M, Thorne D, Sing HC, Fertig J (1989) The effects of d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacology 2:153-164
22. Mason ST (1983) The neurochemistry and pharmacology of extinction behavior. Neurosci Biobehav Rev 7:325-347
23. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191-225
24. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846
25. Benedict RH, Zivadinov R (2007) Reliability and validity of neuropsychological screening and assessment strategies in MS. J Neurol 254(Suppl 2):II22-II25
26. Rao SM (1991) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. National Multiple Sclerosis Society, New York
27. Gronwall DMA (1977) Paced auditory serial addition task: a measure of recovery from concussion. Percept Mot Skills 44:367-373
28. Smith A (1982) Symbol digit modalities test: Manual. Western Psychological Services, Los Angeles
29. Benedict RH (1997) Brief Visuospatial Memory Test - Revised: Professional Manual. Psychological Assessment Resources, Odessa, Florida
30. Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test: Adult version. Psychological Corporation, San Antonio, TX
31. Langdon D, Amato M, Boringa J, Brochet B, Foley F, Fredrikson S, Hamalainen P, Hartung HP, Krupp L, Penner I, Reder A, Benedict R (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18:891-898
32. Roth RM, Isquith PK, Gioia GA (2005) Behavioral Rating Inventory of Executive Function - Adult version. Psychological Assessment Resources, Lutz
33. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121-1123
34. Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B (2003) Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler 9:393-396
35. Beck AT, Steer RA, Brown GK (2000) BDI-Fast Screen for Medical Patients: Manual. Psychological Corporation, San Antonio, TX
36. Heal DJ, Smith SL, Kulkarni RS, Rowley HL (2008) New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 90:184-197
37. Sagvolden T, Xu T (2008) l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 4:3
38. Izquierdo I, Medina JH (1997) Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 68:285-316
39. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH (2010) Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 16:228-237
40. Brochet B, Deloire MS, Bonnet M, Salort-Campana E, Ouallet JC, Petry KG, Dousset V (2008) Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler 14:1242-1249
41. Morrow S, O'Connor P, Polman C, Goodman A, Kappos L, Lublin F, Rudick R, Jurgensen S, Paes D, Forrestal F, Benedict R (2010) Evaluation of the Symbol Digit Modalities Test (SDMT) and MS Neuropsychological Screening Questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 16:1385-1392
42. Benedict RH, Duquin JA, Jurgensen S, Rudick RA, Feitcher J, Munschauer FE, Panzara MA, Weinstock-Guttman B (2008) Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 14:940-946
43. DeLuca J, Gaudino EA, Diamond BJ, Christodoulou C, Engel RA (1998) Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol 20:376-390
44. Gioia G, Isquith P, Guy S, Kenworthy L (2000) The Behavior Rating Inventory of Executive Function. Psychological Assessment Resources, Lutz, FL
45. Benedict RH, Munschauer F, Linn R, Miller C, Murphy E, Foley F, Jacobs L (2003) Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 9:95-101
46. Deloire MS, Bonnet MC, Salort E, Arimone Y, Boudineau M, Petry KG, Brochet B (2006) How to detect cognitive dysfunction at early stages of multiple sclerosis? Mult Scler 12:445-452
47. Benedict RH, Walton MK (2012) Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change? Mult Scler. doi: 10.1177/1352458512454774
48. FDA (2010) Vyvanse (lisdexamfetamine dimesylate). Prescribing information. US Department of Health and Human Services
49. Lower EE, Harman S, Baughman RP (2008) Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 133(5):1189-1195
50. Roth AJ, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, O'Shea N, Arauz G, Breitbart W (2010) Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 116:5102-5110
51. Gore RK, Webb TS, Hermes ED (2010) Fatigue and stimulant use in military fighter aircrew during combat operations. Aviat Space Environ Med 81:719-727
52. Kirkpatrick MG, Haney M, Vosburg SK, Comer SD, Foltin RW, Hart CL (2009) Methamphetamine self-administration by humans subjected to abrupt shift and sleep schedule changes. Psychopharmacology 203:771-780
53. Peuckmann-Post V, Elsner F, Krumm N, Trottenberg P, Radbruch L (2010) Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews, Issue 11. Art. No.: CD006788. doi: 10.1002/14651858.CD006788.pub2
54. Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RH (2009) Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Mult Scler 15:998-1005